BLCM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Mar 2024 @ 14:59):

Stats
Today's Volume	6 059.00
Average Volume	28 581.00
Market Cap	778 326
EPS	$0 ( 2024-03-29 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-22	Baker Bros. Advisors Lp	Sell	1 941 607	Warrants (right to buy)
2023-11-22	Baker Bros. Advisors Lp	Buy	1 941 607	Common Stock
2023-11-22	Baker Bros. Advisors Lp	Sell	174 742	Warrants (right to buy)
2023-11-22	Baker Bros. Advisors Lp	Buy	174 742	Common Stock
2023-05-05	Baker Bros. Advisors Lp	Buy	0	Common Stock

INSIDER POWER
9.84
Last 91 transactions
Buy: 8 287 527 \| Sell: 2 332 728

Bellicum Pharmaceuticals Correlation

10 Most Positive Correlations
CNDT	0.957
FOSL	0.943
VTRS	0.932
TBNK	0.928
SRTS	0.927
RPAY	0.925
FNWB	0.923
GTEC	0.922
LPCN	0.919
GRPN	0.918

10 Most Negative Correlations
TYHT	-0.933
NRDS	-0.905
BLCT	-0.897
CNST	-0.889
EPZM	-0.888
CNCE	-0.878
FLXN	-0.874
XOG	-0.872
AMRB	-0.869
HUGE	-0.86

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bellicum Pharmaceuticals Financials

Annual	2022
Revenue:	$1.50M
Gross Profit:	$1.50M (100.00 %)
EPS:	$-0.810

Q3	2023
Revenue:	$1.00M
Gross Profit:	$1.00M (100.00 %)
EPS:	$-0.0247

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.240

Q1	2023
Revenue:	$8 000.00
Gross Profit:	$8 000.00 (100.00 %)
EPS:	$-0.240

Financial Reports:

No articles found.

Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.